INOVIO PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.57 USD | +4.40% |
|
+9.19% | +72.71% |
| Sales 2024 * | 604K 826K | Sales 2025 * | 8.03M 10.98M | Capitalization | 274M 374M |
|---|---|---|---|---|---|
| Net income 2024 * | -99M -135M | Net income 2025 * | -93M -127M | EV / Sales 2024 * | 453 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 34.1 x |
| P/E ratio 2024 * |
-2.74
x | P/E ratio 2025 * |
-3.5
x | Employees | 122 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.51% |
More Fundamentals
* Assessed data
More news
Latest transcript on Inovio Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | +4.40% | ||
| 1 week | +9.19% | ||
| Current month | -23.85% | ||
| 1 month | -18.88% | ||
| 3 months | +71.87% | ||
| 6 months | +139.75% | ||
| Current year | +72.71% |
1 week
9.29
10.82
1 month
8.3514.75
Current year
4.7314.75
1 year
3.8914.75
3 years
3.89123.96
5 years
3.89405.48
10 years
3.89405.48
| Managers | Title | Age | Since |
|---|---|---|---|
Jacqueline Shea
CEO | Chief Executive Officer | 58 | 19-03-24 |
Peter Kies
DFI | Director of Finance/CFO | 60 | 02-05-31 |
| Chief Tech/Sci/R&D Officer | - | 07-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Simon Benito
CHM | Chairman | 79 | 03-11-30 |
Lota Zoth
BRD | Director/Board Member | 64 | 17-12-31 |
Jay Shepard
BRD | Director/Board Member | 66 | 20-01-14 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.04% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 10.57 | +4.40% | 196,113 |
| 24-04-25 | 10.12 | -0.34% | 154,741 |
| 24-04-24 | 10.16 | -2.03% | 246,812 |
| 24-04-23 | 10.37 | +3.49% | 242,734 |
| 24-04-22 | 10.02 | +3.51% | 335,745 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotes
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
10.57
USD
Average target price
19.25
USD
Spread / Average Target
+82.12%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +72.71% | 274M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- INO Stock
